Faculty

Fay Wright headshot

Fay Wright

APRN-BC PhD RN

Assistant Professor

1 914 672 4231

433 First Avenue
Room 508
New York, NY 10010
United States

expand all

collapse all

Professional overview

Dr. Wright is Assistant Professor of Nursing. She received a B.S.N. and M.S. from University of Michigan School of Nursing, and a Ph.D. from New Your University College of Nursing.

Fay Wright, PhD, RN, APRN-BC joined the Rory Meyers College of Nursing as an assistant professor in 2015, following a T-32 post-doctoral fellowship in Self and Symptom Management at Yale University School of Nursing. Dr. Wright’s research is focused on identifying profiles of patients at risk for higher levels of symptoms with chronic comorbid conditions including cancer, heart disease and diabetes. By developing risk profiles that incorporate demographic, clinical and genomic characteristics, Dr. Wright plans to develop and test precision interventions to support patients’ self-management of symptoms, and to improve their functional status and quality of life. Dr. Wright has experience conducting clinical research within large urban and community hospital settings using quantitative, biobehavioral and mixed method methodology. Her publications identify characteristics of patients at risk for higher levels of fatigue during chemotherapy.

Prior to joining the faculty at NYU, Dr. Wright the Assistant Director for Evidence-Based Practice and Nursing Research at Northern Westchester Hospital in Mt Kisco NY, a clinical assistant professor at Pace University Lienhard School of Nursing, and NYU College of Nursing.

Education

New York University, PhD
New York University, Post-Master's Certificate
University of Michigan School of Nursing, MS
University of Michigan School of Nursing, BSN

Honors and awards

Research Pilot Grant International Society of Nurses in Genetics: Daily Diurnal Fatigue Variability and its Association with Genetic Expression of Inflammasome Pathways $2500 (2017)
T32 Post-doctoral fellowship, National Institute of Nursing Research (2017)
Intramural Research Training Award: Precision Health Boot Camp. National Institute of Nursing (2016)
Intramural Research Training Award: Summer genetics Institute. National Institute of Nursing. (2015)
Summer Genetics Institute. Intramural Research Training Award National Institute of Nursing Research. (2015)
Valedictorian PhD Program New York University College of Nursing (2015)
Distinguished PhD Student New York University College of Nursing (2015)
Best Dissertation Award New York University College of Nursing (2015)
Evidence-Based Practice Excellence Award Maintaining Normothermia in Perioperative Patients Foundation of New York State Nurses Association (2012)
Evidence-Based Practice Excellence Award: Developing an Evidence-based Protocol for Sedation in Mechanically Ventilated Critical Care Patients Foundation of New York State Nurses Association (2011)

Professional membership

Eastern Nursing Research Society (Chronic Comorbid Conditions Research Interest Group Co-Chair)
Sigma Theta Tau
Oncology Nursing Society
American Nurses Association
Association of New York State Nurses

Publications

Publications

Changes in the Occurrence, Severity, and Distress of Symptoms in Patients With Gastrointestinal Cancers Receiving Chemotherapy

Tantoy, I. Y., Cooper, B. A., Dhruva, A., Cataldo, J., Paul, S. M., Conley, Y. P., Hammer, M., Wright, F., Dunn, L. B., Levine, J. D., & Miaskowski, C. (2018). Journal of Pain and Symptom Management. 10.1016/j.jpainsymman.2017.10.004
Abstract
Context: Studies on multiple dimensions of the symptom experience of patients with gastrointestinal cancers are extremely limited. Objective: Purpose was to evaluate for changes over time in the occurrence, severity, and distress of seven common symptoms in these patients. Methods: Patients completed Memorial Symptom Assessment Scale, six times over two cycles of chemotherapy (CTX). Changes over time in occurrence, severity, and distress of pain, lack of energy, nausea, feeling drowsy, difficulty sleeping, and change in the way food tastes were evaluated using multilevel regression analyses. In the conditional models, effects of treatment group (i.e., with or without targeted therapy), age, number of metastatic sites, time from cancer diagnosis, number of prior cancer treatments, cancer diagnosis, and CTX regimen on enrollment levels, as well as the trajectories of symptom occurrence, severity, and distress were evaluated. Results: Although the occurrence rates for pain, lack of energy, feeling drowsy, difficulty sleeping, and change in the way food tastes declined over the two cycles of CTX, nausea and numbness/tingling in hands/feet had more complex patterns of occurrence. Severity and distress ratings for the seven symptoms varied across the two cycles of CTX. Conclusions: Demographic and clinical characteristics associated with differences in enrollment levels as well as changes over time in occurrence, severity, and distress of these seven common symptoms were highly variable. These findings can be used to identify patients who are at higher risk for more severe and distressing symptoms during CTX and to enable the initiation of preemptive symptom management interventions.

Implementation of Enhanced Recovery After Surgery in a Community Hospital: An Evidence-Based Approach

Persico, M., Miller, D., Way, C., Williamson, M., O’Keefe, K., Strnatko, D., & Wright, F. (2018). Journal of Perianesthesia Nursing. 10.1016/j.jopan.2018.02.005
Abstract
Purpose: Enhanced recovery after surgery (ERAS) is an evidence-based practice protocol that has been shown to reduce cost, decrease length of stay (LOS), and improve surgical outcomes. Design: An evidence-based practice improvement project with a multidisciplinary team translated the ERAS protocol into practice at a community hospital. The evidence-based practice improvement design allows integration of evidence into projects to improve clinical outcomes for patients. Methods: Small tests of change using the Plan-Act-Study-Do methodology were used to evaluate the process of implementing one surgical service at a time to ensure effective outcomes. After the process was determined to be effective, patient outcomes (eg, LOS) were measured. Findings: On average, LOS was decreased from 3.2 to 1.7 days. Surgical readmission rate decreased from 3% to 1%. There has been positive feedback and nursing workload has decreased with consistent processes. Conclusions: The ERAS order set continues to be modified based on the evidence and feedback from anesthesia and registered nurses. Monthly reports ensure consistency.

Risk Factors Associated With Chemotherapy-Induced Nausea in the Week Before the Next Cycle and Impact of Nausea on Quality of Life Outcomes

Singh, K. P., Kober, K. M., Dhruva, A. A., Flowers, E., Paul, S. M., Hammer, M., Cartwright, F., Wright, F., Conley, Y. P., Levine, J. D., & Miaskowski, C. (2018). Journal of Pain and Symptom Management. 10.1016/j.jpainsymman.2018.05.019
Abstract
Context: Despite current advances in antiemetic treatments, between 19% and 58% of oncology patients experience chemotherapy-induced nausea (CIN). Objectives: Aims of this post hoc exploratory analysis were to determine occurrence, severity, and distress of CIN and evaluate for differences in demographic and clinical characteristics, symptom severity, stress; and quality of life (QOL) outcomes between oncology patients who did and did not report CIN in the week before chemotherapy (CTX). Demographic, clinical, symptom, and stress characteristics associated with CIN occurrence were determined. Methods: Patients (n = 1296) completed questionnaires that provided information on demographic and clinical characteristics, symptom severity, stress, and QOL. Univariate analyses evaluated for differences in demographic and clinical characteristics, symptom severity, stress, and QOL scores between the two patient groups. Multiple logistic regression analysis was used to evaluate for factors associated with nausea group membership. Results: Of the 1296 patients, 47.5% reported CIN. In the CIN group, 15% rated CIN as severe and 23% reported high distress. Factors associated with CIN included less education; having childcare responsibilities; poorer functional status; higher levels of depression, sleep disturbance, evening fatigue, and intrusive thoughts; as well as receipt of CTX on a 14-day CTX cycle and receipt of an antiemetic regimen that contained serotonin receptor antagonist and steroid. Patients in the CIN group experienced clinically meaningful decrements in QOL. Conclusion: This study identified new factors (e.g., poorer functional status, stress) associated with CIN occurrence. CIN negatively impacted patients’ QOL. Pre-emptive and ongoing interventions may alleviate CIN occurrence in high-risk patients.

Characteristics associated with inter-individual differences in the trajectories of self-reported attentional function in oncology outpatients receiving chemotherapy

Shih, J., Leutwyler, H., Ritchie, C., Paul, S. M., Levine, J. D., Cooper, B., Wright, F., Conley, Y. P., & Miaskowski, C. (2017). Supportive Care in Cancer, 25(3), 783-793. 10.1007/s00520-016-3461-2
Abstract
Purpose: Between 14 and 85 % of patients report noticeable changes in cognitive function during chemotherapy (CTX). The purposes of this study were to determine which demographic, clinical, and symptom characteristics were associated with inter-individual variability in initial levels of attentional function as well as with changes in the trajectories of attentional function in a sample of oncology patients who received two cycles of CTX. Methods: Oncology outpatients (n = 1329) were recruited from two comprehensive cancer centers, one veteran’s affairs hospital, and four community-based oncology programs. The Attentional Function Index (AFI) was used to assess perceived effectiveness in completing daily tasks that required working memory and attention. Hierarchical linear modeling (HLM) was used to evaluate for inter-individual variability in initial levels and in the trajectories of attentional function. Results: Demographic, clinical, and symptom characteristics associated with inter-individual differences of attentional function at enrollment (i.e., intercept) were as follows: employment status, functional status, trait anxiety, depressive symptoms, sleep disturbance, evening fatigue, and morning energy. Gender was the only characteristic associated with inter-individual differences in the trajectories of attentional function. Morning fatigue was the only characteristic associated with both initial levels and the trajectories of attentional function. Conclusions: Prior to their next dose of CTX, patients reported moderate levels of attentional function that persisted over two cycles of CTX. Many of the clinical and symptom characteristics associated with decrements in attentional function are amenable to interventions. Clinicians need to assess patients for changes in attentional function and associated characteristics and recommend evidence-based interventions.

Common and Distinct Characteristics Associated With Trajectories of Morning and Evening Energy in Oncology Patients Receiving Chemotherapy

Abid, H., Kober, K. M., Smoot, B., Paul, S. M., Hammer, M., Levine, J. D., Lee, K., Wright, F., Cooper, B. A., Conley, Y. P., & Miaskowski, C. (2017). Journal of Pain and Symptom Management. 10.1016/j.jpainsymman.2016.12.339
Abstract
Context: Although energy conservation strategies are recommended in clinical practice guidelines, little is known about changes in energy levels in oncology patients undergoing cancer treatment. Objectives: The objective of this study was to identify variations in the trajectories of morning and evening energy levels and determine which characteristics predicted initial levels and the trajectories of morning and evening energy. Methods: Outpatients receiving chemotherapy (CTX) completed demographic and symptom questionnaires six times over two CTX cycles. Energy was assessed using the Lee Fatigue Scale. Hierarchical linear modeling was used to analyze the data. Results: A large amount of interindividual variability was found in the morning and evening energy trajectories. Patients who lived alone, had childcare responsibilities, had a lower functional status, did not exercise on a regular basis, had lower hemoglobin levels, had lower attentional function, higher trait anxiety, and higher sleep disturbance reported lower morning energy levels at enrollment. Variations in the trajectories of morning energy were associated with a higher body mass index and higher levels of morning energy and higher sleep disturbance scores. For evening energy, patients who were female, white, had lower functional status, and had lower attentional function and higher sleep disturbance reported lower evening energy levels at enrollment. Evening energy levels at enrollment were associated with changes in evening energy over time. Conclusion: Patients undergoing CTX experience decrements in both morning and evening energy. The modifiable characteristics associated with these decrements can be used to design intervention studies to increase energy levels in these patients.

Congruence Between Latent Class and K-Modes Analyses in the Identification of Oncology Patients With Distinct Symptom Experiences

Papachristou, N., Barnaghi, P., Cooper, B. A., Hu, X., Maguire, R., Apostolidis, K., Armes, J., Conley, Y. P., Hammer, M., Katsaragakis, S., Kober, K. M., Levine, J. D., McCann, L., Patiraki, E., Paul, S. M., Ream, E., Wright, F., & Miaskowski, C. (2017). Journal of Pain and Symptom Management. 10.1016/j.jpainsymman.2017.08.020
Abstract
Context: Risk profiling of oncology patients based on their symptom experience assists clinicians to provide more personalized symptom management interventions. Recent findings suggest that oncology patients with distinct symptom profiles can be identified using a variety of analytic methods. Objectives: The objective of this study was to evaluate the concordance between the number and types of subgroups of patients with distinct symptom profiles using latent class analysis and K-modes analysis. Methods: Using data on the occurrence of 25 symptoms from the Memorial Symptom Assessment Scale, that 1329 patients completed prior to their next dose of chemotherapy (CTX), Cohen's kappa coefficient was used to evaluate for concordance between the two analytic methods. For both latent class analysis and K-modes, differences among the subgroups in demographic, clinical, and symptom characteristics, as well as quality of life outcomes were determined using parametric and nonparametric statistics. Results: Using both analytic methods, four subgroups of patients with distinct symptom profiles were identified (i.e., all low, moderate physical and lower psychological, moderate physical and higher Psychological, and all high). The percent agreement between the two methods was 75.32%, which suggests a moderate level of agreement. In both analyses, patients in the all high group were significantly younger and had a higher comorbidity profile, worse Memorial Symptom Assessment Scale subscale scores, and poorer QOL outcomes. Conclusion: Both analytic methods can be used to identify subgroups of oncology patients with distinct symptom profiles. Additional research is needed to determine which analytic methods and which dimension of the symptom experience provide the most sensitive and specific risk profiles.

Differences in Symptom Clusters Identified Using Ratings of Symptom Occurrence vs. Severity in Lung Cancer Patients Receiving Chemotherapy

Wong, M. L., Cooper, B. A., Paul, S. M., Levine, J. D., Conley, Y. P., Wright, F., Hammer, M., & Miaskowski, C. (2017). Journal of Pain and Symptom Management. 10.1016/j.jpainsymman.2017.04.005
Abstract
Context: An important question in symptom clusters research is whether the number and types of symptom clusters vary based on the specific dimension of the symptom experience used to create the clusters. Objectives: Given that lung cancer patients undergoing chemotherapy (CTX) report an average of 14 co-occurring symptoms and studies of symptom clusters in these patients are limited, the purpose of this study, in lung cancer patients undergoing CTX (n = 145), was to identify whether the number and types of symptom clusters differed based on whether symptom occurrence rates or symptom severity ratings were used to create the clusters. Methods: A modified version of the Memorial Symptom Assessment Scale was used to assess for the occurrence and severity of 38 symptoms, one week after the administration of CTX. Exploratory factor analysis was used to extract the symptom clusters. Results: Both the number and types of symptom clusters were relatively similar using symptom occurrence rates or symptom severity ratings. Five symptom clusters were identified using both symptom occurrence rates and severity ratings (i.e., sickness behavior, lung cancer specific, psychological, nutritional, and epithelial). Across these two dimensions, the specific symptoms within each of the symptom clusters were relatively similar. Conclusions: Identification of symptom clusters in patients with lung cancer may assist with the development of more targeted symptom management interventions. Future studies are warranted to determine if symptom clusters change over a cycle of CTX in patients with lung cancer.

Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy

Tantoy, I. Y., Dhruva, A., Cataldo, J., Venook, A., Cooper, B. A., Paul, S. M., Levine, J. D., Conley, Y. P., Cartwright, F., Lee, K., Wright, F., & Miaskowski, C. (2017). Journal of Gastrointestinal Oncology, 8(1), 109-126. 10.21037/jgo.2017.01.09
Abstract
Background: Approximately 28% of patients with gastrointestinal (GI) cancers will receive targeted therapy (TT) because of the associated increases in survival. Only four studies have examined the symptom experience of these patients. To date, no studies have evaluated for differences in symptom occurrence, severity, and distress between patients who received chemotherapy (CTX) alone (n=304) or CTX with TT (n=93). Methods: Patients completed self-report questionnaires, approximately one week after they received CTX. A modified version of the Memorial Symptom Assessment Scale (MSAS) was used to obtain data on symptom occurrence, severity, and distress. Binary logistic regression analyses were used to test for differences in symptom occurrence rates between the two treatment groups. Ordinal logistic regression analyses were used to test for differences in severity and distress ratings between the two treatment groups. Results: Patients who received CTX with TT were significantly younger (P=0.009); were diagnosed with cancer longer (P=0.004); had a higher number of prior treatments (P=0.024); had metastatic disease, specifically to the liver (P < 0.001); had a diagnosis of anal, colon, rectum, or colorectal cancer (CRC) (P < 0.001); and were positive for detection of B-Raf proto-oncogene, serine/threonine kinase (BRAF) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (both P < 0.001). In addition, CTX treatment regimens were significantly different between the two groups (P < 0.001). After controlling for significant covariates, patients who received TT reported lower occurrence rates for lack of energy, cough, feeling drowsy, and difficulty sleeping (all, P < 0.05). Patients who received TT reported lower severity scores for dry mouth (P=0.034) and change in the way food tastes (P=0.035). However, they reported higher severity scores for "I don't look like myself" (P=0.026). No differences in symptom distress scores were found between the two treatment groups. Conclusions: This study is the first to evaluate for differences in the symptom experience of GI cancer patients who received CTX alone or CTX with TT using a multidimensional symptom assessment scale. While between group differences in patients' symptom experiences were identified, both treatment groups warrant ongoing assessments to optimally manage their symptoms.

Differential expression of genes and differentially perturbed pathways associated with very high evening fatigue in oncology patients receiving chemotherapy

Flowers, E., Miaskowski, C., Conley, Y., Hammer, M., Levine, J., Mastick, J., Paul, S., Wright, F., & Kober, K. (2017). Supportive Care in Cancer, 1-12. 10.1007/s00520-017-3883-5
Abstract
Purpose: Fatigue is the most common symptom associated with cancer and its treatment. Investigation of molecular mechanisms associated with fatigue in oncology patients may identify new therapeutic targets. The objectives of this study were to evaluate the relationships between gene expression and perturbations in biological pathways and evening fatigue severity in oncology patients who received chemotherapy (CTX). Methods: The Lee Fatigue Scale (LFS) and latent class analysis were used to identify evening fatigue phenotypes. We measured 47,214 ribonucleic acid transcripts from whole blood collected prior to a cycle of CTX. Perturbations in biological pathways associated with differential gene expression were identified from public data sets (i.e., Kyoto Encyclopedia Gene and Genomes, BioCarta). Results: Patients were classified into Moderate (n = 65, mean LFS score 3.1) or Very High (n = 195, mean LFS score 6.4) evening fatigue groups. Compared to patients with Moderate fatigue, patients with Very High fatigue exhibited differential expression of 29 genes. A number of the perturbed pathways identified validated prior mechanistic hypotheses for fatigue, including alterations in immune function, inflammation, neurotransmission, energy metabolism, and circadian rhythms. Based on our findings, energy metabolism was further divided into alterations in carbohydrate metabolism and skeletal muscle energy. Alterations in renal function-related pathways were identified as a potential new mechanism. Conclusions: This study identified differential gene expression and perturbed biological pathways that provide new insights into the multiple and likely inter-related mechanisms associated with evening fatigue in oncology patients.

Distinct evening fatigue profiles in oncology outpatients receiving chemotherapy

Wright, F., Cooper, B., Conley, Y., Hammer, M., Chen, L., & Al.,. (2017). Fatigue: Biomedicine, Health and Behavior, 5(3), 131-144. 10.1080/21641846.2017.1322233